News | Patient Positioning Radiation Therapy | January 16, 2017

Augmenix Announces Positive Three-Year Long-Term Data for SpaceOAR Hydrogel Spacer

Results show on average no long-term declines in bowel and urinary quality of life for patients, and 78 percent reduction in late rectal toxicity

Augmenix, SpaceOAR hydrogel spacer, three-year trial data, Red Journal, prostate cancer radiotherapy

January 16, 2017 — Augmenix Inc. announced that the International Journal of Radiation Oncology Biology and Physics (IJROBP), also known as the Red Journal, has published long-term outcomes data from the company’s Phase 3 clinical trial for SpaceOAR System. SpaceOAR is the first absorbable hydrogel spacer designed to separate the rectum and prostate during prostate cancer radiotherapy.

The Red Journal publication reports three-year post-treatment data in the Phase 3 prospective, randomized, multi-center, patient-blinded clinical trial of the SpaceOAR System. The study evaluated radiation dose to critical structures (prostate, rectum, bladder, penile bulb), rectal and urinary toxicity, and quality of life (QOL) impact on prostate cancer patients treated with and without SpaceOAR System during radiotherapy. For QOL, the Expanded Prostate Cancer Index Composite (EPIC) was utilized. The SpaceOAR System is the only product that is U.S. Food and Drug Administration (FDA)-cleared to provide a barrier between the prostate and rectum to decrease toxicity and minimize changes in QOL following prostate radiotherapy. It is injected as a liquid and then solidifies into a soft hydrogel that pushes the rectum out of the high-dose prostate radiation field for three months during radiation therapy. The hydrogel is absorbed by the body in the months following treatment.

During radiotherapy the spacer resulted in a 73.5 percent reduction in rectal V70 radiation dose, and a 49 percent reduction in median penile bulb radiation dose in patients treated with SpaceOAR (SpaceOAR) compared to men who did not receive SpaceOAR hydrogel (Control). In the three years following radiation treatment the SpaceOAR group demonstrated a 78 percent reduction in late rectal toxicity complications, compared to Control patients. No patients in the SpaceOAR group (0 percent) experienced grade two or worse rectal toxicity, compared to 5.7 percent in the Control group. Results also showed a 75 percent reduced risk of mild urinary incontinence among patients treated with SpaceOAR compared to Control. At three years, the average SpaceOAR patient bowel and urinary QOL measure was the same as before radiotherapy, while the Control patients QOL measures had significantly declined.1

Overall patient wellness at three years was also assessed by looking at the percent of patients with clinically significant declines in all three QOL areas (bowel, urinary and sexual). Fully 20 percent (one in five) of the Control patients had clinically significant QOL declines in all three QOL areas, compared to only 2.5 percent (one in forty) of the SpaceOAR patients.

“These results further validate the safety and efficacy of the SpaceOAR System and highlight the long-term benefits it can provide to prostate cancer patients who are treated with radiotherapy,” said Daniel Hamstra, M.D., Ph.D., radiation oncologist at Texas Center for Proton Therapy. “By creating a space between the rectum and prostate, SpaceOAR can help prevent risks of injury to surrounding healthy tissue during radiation, representing an important advantage for thousands of men treated for prostate cancer each year.”

For more information: www.spaceoar.com

References

1. Hamstra, D.A., Mariados, N., Sylvester, J., Shah, D., et al. "Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial." International Journal of Radiation Oncology Biology Physics. Published online Dec. 22, 2016.

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc